“ATLANTA – Maintenance treatment with the PARP inhibitor rucaparib (Rubraca) was well tolerated and provided clinical responses among patients...
ATLANTA – A common single nucleotide polymorphism (SNP) was associated with increased risk for developing stroke in childhood survivors...
Patients without insurance were less likely to receive surgery, increasing disparity in outcomes ATLANTA – Surgery was associated with...
ATLANTA – The experimental oncolytic adenovirus telomelysin (OBP-301) in combination with radiotherapy was safe and showed early clinical efficacy...
ATLANTA – Prostate cancer incidence and mortality rates are decreasing or stabilizing in most parts of the world, with...
ATLANTA – A combination of the experimental histone deacetylase (HDAC) inhibitor entinostat with the anti-PD-1 therapeutic pembrolizumab (Keytruda) showed...
ATLANTA – The investigational anticancer therapeutic LOXO-195 (now known as BAY 2731954), which targets a family of proteins called...
Dr. Elaine R. Mardis inaugurated as President ATLANTA – The American Association for Cancer Research (AACR) welcomes Elaine R....
ATLANTA – The anti-PD-1 monoclonal antibody pembrolizumab (Keytruda) showed promising antitumor activity with durable responses in patients with pretreated,...
ATLANTA – The investigational therapeutic umbralisib, which targets the molecule PI3K-delta, was well tolerated and highly active in patients...